Gastrointestinal

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AstraZeneca) D910DC00001 / EMERALD-2A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation.Meyers, Dr BrandonOpen to recruitmentNCT03847428
(CCTG) CO.29 / DYNAMIC IIICirculating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study (DYNAMIC III)Goffin, Dr JohnOpen to recruitmentACTRN12617001566325
(CCTG) CRC.9 / NRG-GI005Phase II/III Study of Circulating tumOr DNA as a Predictive BiomarRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)Meyers, Dr BrandonOpen to recruitmentNCT04068103
(Merck) MK-7902-015 / LEAP 015A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma. Juergens, Dr RosalynOpen to recruitmentNCT04662710
(Roche) MO42541 / IMbrave251A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS SORAFENIB OR LENVATINIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATEDWITH ATEZOLIZUMAB AND BEVACIZUMABMeyers, Dr BrandonOpen to recruitmentNCT04770896
(CCTG) CO.21 / CHALLENGEA Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE)Goffin, Dr JohnSuspended/On holdNCT00819208
Download PDF